Crispr Therapeutics price target raised to $93 from $78 at BofA

BofA raised the firm’s price target on Crispr Therapeutics (CRSP) to $93 from $78 and keeps a Buy rating on the shares. The firm, which continues to see Casgevy growth in the near-term, updated its model to include revenue builds for several in vivo gene editing programs, CTX112 in autoimmune conditions, and SRSD107, adding that it believes the company’s pipeline potential is “underappreciated.”